Cancer deaths linked to obesity have tripled in the United States over the past two decades, according to a study presented at ENDO 2025 in July.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
